微滔生物获启明创投领投超亿元天使轮融资，引领体内CAR-T技术变革

Core Insights - Weitao Biotech has completed over 100 million RMB in angel round financing, led by Qiming Venture Partners, with funds aimed at optimizing core technology platforms and advancing clinical development of its first candidate product in autoimmune diseases [2][3] Company Overview - Weitao Biotech, established on June 25, 2025, is a spin-off from Beijing Shali Bio-pharmaceutical Co., Ltd., focusing on in vivo CAR-T therapy [2] - The company aims to revolutionize treatment for hematological malignancies and autoimmune diseases by enabling CAR expression directly in patient T cells, eliminating the need for traditional autologous CAR-T therapy processes [2] Technology and Innovation - Weitao Biotech's in vivo CAR-T therapy utilizes a targeted LNP delivery system, which enhances targeting efficiency, safety, and production compatibility, effectively reducing off-target risks [3] - The proprietary technology allows for efficient T cell activation and long-lasting CAR expression, demonstrating excellent B cell clearance effects in preclinical models and good safety for repeated dosing [3] Investment and Future Plans - Qiming Venture Partners, as the lead investor, emphasizes the global leading potential of Weitao Biotech's targeted LNP delivery platform in addressing traditional CAR-T therapy challenges [4] - The CEO of Weitao Biotech expresses commitment to filling unmet clinical needs through technological innovation, with the recent financing expected to accelerate clinical validation of its in vivo CAR-T pipeline [4]